NCT07342114

A Dose-Escalation Study of RO7875913 in Healthy Participants

A Phase I Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	RO7875913	Participants will receive RO7875913 as per the schedule described in the protocol.
DRUG	Placebo	Participants will receive placebo as per the schedule described in the protocol.

Timeline

• Start date: 2026-03-11
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2026-01-15
• Last updated: 2026-03-30

Locations

1 site across 1 country: New Zealand